Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Breast 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

Paclitaxel 162Fulvestrant 157Trastuzumab 156pembrolizumab 146Letrozole 137Carboplatin 118Capecitabine 105pertuzumab 104Specimen Handling 102Cyclophosphamide 102Anastrozole 90palbociclib 86abemaciclib 82Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 74trastuzumab deruxtecan 70Radiotherapy 62Biopsy 59Surveys and Questionnaires 56Gemcitabine 53130-nm albumin-bound paclitaxel 53olaparib 52sacituzumab govitecan 51Blood Specimen Collection 51Standard of Care 49Taxes 48eribulin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Chromatin Immunoprecipitation Sequencing × Breast × 1 year × Clear all
NCT07291414 2026-01-21

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

University of Michigan Rogel Cancer Center

Phase NA Recruiting
80 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT07294430 2025-12-19

OASISImmunoPET

UNICANCER

Phase 2 Not yet recruiting
30 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡